Results of Operations and Financial Condition. On August 26, 2026, BeOne Medicines Ltd. (the “Company”) filed its 2026 Interim Report for the six months ended June 30, 2026 (the “STAR Interim Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange, which was prepared in accordance with the listing rules of the STAR Market and the applicable securities laws and regulations of the Peoples’ Republic of China (the “PRC” and the “PRC Securities…

of this Current Report on Form 8-K are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing. Exhibit Index Exhibit No. Description 99.1 Press relea…

Director — Michael Goller, Ranjeev Krishana, Corazon (Corsee) D. Sanders, Qingqing Yi: The directors did not stand for re-election at the Annual Meeting.

of this Current Report on Form 8-K are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing. Exhibit Index Exhibit No. Description 99.1 Press relea…

Results of Operations and Financial Condition. On April 14, 2026, BeOne Medicines Ltd. (the “Company”) filed its 2025 Annual Report (the “STAR Annual Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange, which was prepared in accordance with the listing rules of the STAR Market and the applicable securities laws and regulations of the Peoples’ Republic of China (the “PRC” and the “PRC Securities Laws”). As required by the PRC Securities…

of this Current Report on Form 8-K are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing. Exhibit Index Exhibit No. Description 99.1 Press relea…

Termination of a Material Definitive Agreement. As previously disclosed in its Current Report on Form 8-K filed on November 19, 2025, BeOne Medicines Ltd. (the “Company”) entered into the Facilities Agreement (the “Facilities Agreement”), by and among (i) certain subsidiaries of the Company listed in the Facilities Agreement, as guarantors, (ii) The Hongkong and Shanghai Banking Corporation Limited, as global coordinator, original mandated lead arranger and bookrunner, agent and security agen…

President, Global Head of Research and Development — Dr. Lai Wang: Dr. Lai Wang was promoted to President, Global Head of Research and Development.

Entry into a Material Definitive Agreement. Entry into Facilities Agreement On November 13, 2025 (November 14, 2025 Hong Kong time), BeOne Medicines Ltd. (the “Company” and, together with its subsidiaries, the “Group”) entered into the Facilities Agreement (the “Facilities Agreement”), by and among (i) certain subsidiaries of the Company listed in the Facilities Agreement, as guarantors (the “Guarantors”), (ii) The Hongkong and Shanghai Banking Corporation Limited (“HSBC”), as global coordina…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information required by this

of this Current Report on Form 8-K are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing. Exhibit Index Exhibit No. Description 99.1 Press relea…

Results of Operations and Financial Condition. On August 29, 2025, BeiGene, Ltd. (the “Company”) filed its 2025 Interim Report for the six months ended June 30, 2025 (the “STAR Interim Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange, which was prepared in accordance with the listing rules of the STAR Market and the applicable securities laws and regulations of the Peoples’ Republic of China (the “PRC” and the “PRC Securities Laws”).…

Entry into a Material Definitive Agreement. On August 25, 2025, BeOne Medicines Ltd. (the “Company”), BeOne Medicines I GmbH (the “Seller”), a subsidiary of the Company, and Royalty Pharma Investments 2023 ICAV (“Royalty Pharma”) entered into a Royalty Purchase Agreement (the “Royalty Purchase Agreement”). Pursuant to the Royalty Purchase Agreement, in exchange for an upfront payment of $885 million to be paid to the Seller at closing, Royalty Pharma purchased from the Seller a significant po…

of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Re…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The Company has evaluated the Royalty Purchase Agreement and expects that the upfront payment from Royalty Pharma would become a material direct financial obligation of the Company at closing. In addition, the information required by this

of this Current Report on Form 8-K are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing. Exhibit Index Exhibit No. Description 99.1 Press relea…

Unregistered Sales of Equity Securities. On May 13, 2025, in connection with the proposed re-domiciliation of BeiGene, Ltd. (the “Company”) from Cayman Islands to Switzerland (the “Continuation”), the Company entered into an internal transfer agreement with its wholly owned subsidiary, BG NC 2, Ltd., a company incorporated in the Cayman Islands with limited liability (“BGNC2”), pursuant to which the Company will issue an aggregate of 133,000,000 ordinary shares of the Company (the “New Shares…

of this Current Report on Form 8-K are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing. Exhibit Index Exhibit No. Description 99.1 Press relea…

Other Events. On April 29, 2025, the U.S. Patent and Trademark Office (“USPTO”) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (“Pharmacyclics”) U.S. Patent No. 11,672,803 (the “Patent”) that were challenged by BeiGene, Ltd. (the “Company”) in a post-grant review (“PGR”) proceeding. Previously, on November 1, 2023, the Company filed a PGR petition with the USPTO challenging the validity of certain claims of the Patent in response to a patent infringement laws…

Results of Operations and Financial Condition. On April 28, 2025, BeiGene, Ltd. (the “Company”) filed its 2024 Annual Report (the “STAR Annual Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange, which was prepared in accordance with the listing rules of the STAR Market and the applicable securities laws and regulations of the Peoples’ Republic of China (the “PRC” and the “PRC Securities Laws”). As required by the PRC Securities Laws, t…

of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing. Exhibit Index Exhibit No. Description 99.1 Press release titled “BeiGene A…

of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Please see the disclosure set forth under Item 1.01, which is incorporated by reference into this

Entry into a Material Definitive Agreement. On December 9, 2024 (the “Signing Date”), a facility agreement (the “Facility Agreement”) was entered into by and between BeiGene, Ltd. (the “Company”), as the borrower, and China Merchants Bank Co., Ltd., as the lender (the “Lender”). The Facility Agreement provides for a $400 million uncommitted and unsecured credit facility (the “Credit Facility”), pursuant to which each loan issued has a term up to one year, provided that all loans must be repai…

Other Events. On November 14, 2024, BeiGene USA, Inc. and BeiGene Switzerland GmbH (collectively, “BeiGene”), each a subsidiary of BeiGene, Ltd. (the “Company”), entered into a settlement agreement (the “Settlement Agreement”) with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. (collectively “MSN”) resolving patent litigation related to the Company’s product, BRUKINSA ® (zanubrutinib). The patent litigation was brought by BeiGene against MSN in response to MSN’s filing of an Abbr…